IO360˚convenes stakeholders from the science and business communities to report on the latest data impacting IO to fight a wider range of cancers. Reach out if you would like to meet with our staff at this event.
Panel “Assessing the Opportunities for IO 2.0”
Thursday, March 17, 2022, 12:05pm EDT
Innovators continue to mine the tumor microenvironment (TME) for IO therapies 2.0 to extend the utility of checkpoint inhibitors. While there remains an over-focus in the industry on follow-on agents, the diversity of next generation platforms, modalities and targets is promising for extending clinical benefit to patients. This panel will share how they are thinking about clinical strategies moving forward, how they are going to fund them and address the challenges/opportunities in this incredibly competitive space.
Jeff Bockman, EVP & Head of Oncology, Cello Health BioConsulting
-Jacob Becraft, CEO & Co-founder, Strand Therapeutics
-Sharon Benzeno, Chief Business Development Officer, Adaptive Biotechnologies Corp.
-Ariella Evenzahav, PhD, Executive Director, Global Development Strategy, BeiGene
-Prakash Raman, President & CEO, Ribon Therapeutics
-Michael King, Managing Director, HC Wainwright & Co.